Henry Rodriguez

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. doi request reprint Proteomics: a long and winding road to medical diagnostics
    Henry Rodriguez
    Director Clinical Proteomic Technologies for Cancer, Office of the Director, Office of Technology and Industrial Relations, National Cancer Institute, 31 Center Drive, MS 2590, Bethesda, MD 20892, USA 1 301 496 1550
    Expert Opin Med Diagn 3:219-25. 2009
  2. pmc Recommendations from the 2008 International Summit on Proteomics Data Release and Sharing Policy: the Amsterdam principles
    Henry Rodriguez
    Center for Strategic Scientific Initiatives, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Proteome Res 8:3689-92. 2009
  3. doi request reprint Analytical validation of protein-based multiplex assays: a workshop report by the NCI-FDA interagency oncology task force on molecular diagnostics
    Henry Rodriguez
    National Cancer Institute Food and Drug Administration Interagency Oncology Task Force on Molecular Diagnostics, National Institutes of Health, Bethesda, MD 20892, USA
    Clin Chem 56:237-43. 2010
  4. doi request reprint Recommendations for mass spectrometry data quality metrics for open access data (corollary to the Amsterdam principles)
    Christopher R Kinsinger
    Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Proteomics 12:11-20. 2012
  5. pmc Recommendations for mass spectrometry data quality metrics for open access data (corollary to the Amsterdam Principles)
    Christopher R Kinsinger
    Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, United States
    J Proteome Res 11:1412-9. 2012
  6. pmc Recommendations for mass spectrometry data quality metrics for open access data (corollary to the Amsterdam Principles)
    Christopher R Kinsinger
    Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Mol Cell Proteomics 10:O111.015446. 2011
  7. pmc Restructuring proteomics through verification
    Emily Boja
    Office of Cancer Clinical Proteomics Research, Center for Strategic Scientific Initiative, National Cancer Institute, NIH, 31 Center Drive, MS 2590, Bethesda, MD 20892, USA
    Biomark Med 4:799-803. 2010
  8. pmc The path to clinical proteomics research: integration of proteomics, genomics, clinical laboratory and regulatory science
    Emily S Boja
    Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Korean J Lab Med 31:61-71. 2011
  9. doi request reprint Reconstructing the pipeline by introducing multiplexed multiple reaction monitoring mass spectrometry for cancer biomarker verification: an NCI-CPTC initiative perspective
    Henry Rodriguez
    Office of Cancer Clinical Proteomics Research, Center for Strategic Scientific Initiative, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Proteomics Clin Appl 4:904-14. 2010
  10. doi request reprint Evolution of clinical proteomics and its role in medicine
    Emily Boja
    Office of Cancer Clinical Proteomics Research, Center for Strategic Scientific Initiative, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    J Proteome Res 10:66-84. 2011

Detail Information

Publications16

  1. doi request reprint Proteomics: a long and winding road to medical diagnostics
    Henry Rodriguez
    Director Clinical Proteomic Technologies for Cancer, Office of the Director, Office of Technology and Industrial Relations, National Cancer Institute, 31 Center Drive, MS 2590, Bethesda, MD 20892, USA 1 301 496 1550
    Expert Opin Med Diagn 3:219-25. 2009
    ..If the potential of personalized medicine is to be realized, it needs to include this next generation of molecular diagnostics...
  2. pmc Recommendations from the 2008 International Summit on Proteomics Data Release and Sharing Policy: the Amsterdam principles
    Henry Rodriguez
    Center for Strategic Scientific Initiatives, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Proteome Res 8:3689-92. 2009
    ..This summit report explores various approaches to develop a framework of data release and sharing principles that will most effectively fulfill the needs of the funding agencies and the research community...
  3. doi request reprint Analytical validation of protein-based multiplex assays: a workshop report by the NCI-FDA interagency oncology task force on molecular diagnostics
    Henry Rodriguez
    National Cancer Institute Food and Drug Administration Interagency Oncology Task Force on Molecular Diagnostics, National Institutes of Health, Bethesda, MD 20892, USA
    Clin Chem 56:237-43. 2010
    ....
  4. doi request reprint Recommendations for mass spectrometry data quality metrics for open access data (corollary to the Amsterdam principles)
    Christopher R Kinsinger
    Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Proteomics 12:11-20. 2012
    ..The peer review process was a coordinated effort conducted by a panel of referees selected by the journals...
  5. pmc Recommendations for mass spectrometry data quality metrics for open access data (corollary to the Amsterdam Principles)
    Christopher R Kinsinger
    Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, United States
    J Proteome Res 11:1412-9. 2012
    ..The peer review process was a coordinated effort conducted by a panel of referees selected by the journals...
  6. pmc Recommendations for mass spectrometry data quality metrics for open access data (corollary to the Amsterdam Principles)
    Christopher R Kinsinger
    Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Mol Cell Proteomics 10:O111.015446. 2011
    ..The peer review process was a coordinated effort conducted by a panel of referees selected by the journals...
  7. pmc Restructuring proteomics through verification
    Emily Boja
    Office of Cancer Clinical Proteomics Research, Center for Strategic Scientific Initiative, National Cancer Institute, NIH, 31 Center Drive, MS 2590, Bethesda, MD 20892, USA
    Biomark Med 4:799-803. 2010
    ....
  8. pmc The path to clinical proteomics research: integration of proteomics, genomics, clinical laboratory and regulatory science
    Emily S Boja
    Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Korean J Lab Med 31:61-71. 2011
    ....
  9. doi request reprint Reconstructing the pipeline by introducing multiplexed multiple reaction monitoring mass spectrometry for cancer biomarker verification: an NCI-CPTC initiative perspective
    Henry Rodriguez
    Office of Cancer Clinical Proteomics Research, Center for Strategic Scientific Initiative, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Proteomics Clin Appl 4:904-14. 2010
    ....
  10. doi request reprint Evolution of clinical proteomics and its role in medicine
    Emily Boja
    Office of Cancer Clinical Proteomics Research, Center for Strategic Scientific Initiative, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    J Proteome Res 10:66-84. 2011
    ..The availability of these multidimensional data to the scientific community sets the stage for the development of new molecularly targeted cancer interventions...
  11. doi request reprint Mass spectrometry-based targeted quantitative proteomics: achieving sensitive and reproducible detection of proteins
    Emily S Boja
    Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Proteomics 12:1093-110. 2012
    ....
  12. doi request reprint Recommendations for mass spectrometry data quality metrics for open access data (corollary to the Amsterdam principles)
    Christopher R Kinsinger
    Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Proteomics Clin Appl 5:580-9. 2011
    ..The peer review process was a coordinated effort conducted by a panel of referees selected by the journals...
  13. pmc Connecting genomic alterations to cancer biology with proteomics: the NCI Clinical Proteomic Tumor Analysis Consortium
    Matthew J Ellis
    1Division of Oncology and 2Division of Endocrinology and Metabolism, Department of Medicine, Washington University School of Medicine, St Louis, Missouri 3The Broad Institute of MIT and Harvard, Cambridge, Massachusetts 4Fred Hutchinson Cancer Research Center, Seattle 5Biological Sciences Division, Pacific Northwest National Laboratory, Richland, Washington 6Office of Cancer Clinical Proteomics Research, National Cancer Institute, NIH, Bethesda, Maryland and 7The Jim Ayers Institute for Cancer Detection and Diagnosis, Vanderbilt Ingram Cancer Center, Nashville, Tennessee
    Cancer Discov 3:1108-12. 2013
    ....
  14. doi request reprint A synopsis of the 3rd annual Cancer Proteomics Conference
    Mehdi Mesri
    Office of Cancer Clinical Proteomics Research, Center for Strategic Scientific Initiative, National Cancer Institute, National Institutes of Health, 31 Center Drive, Bethesda, MD 20892, USA
    Expert Rev Proteomics 7:815-7. 2010
    ..Delegates had access to both meetings, allowing for enhanced interaction among investigators from the closely linked fields of research...
  15. doi request reprint The journey to regulation of protein-based multiplex quantitative assays
    Emily S Boja
    Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Clin Chem 57:560-7. 2011
    ..One key component in the biomarker development pipeline is the understanding of the regulatory science that evaluates diagnostic assay performance through rigorous analytical and clinical review criteria...
  16. doi request reprint AACR-FDA-NCI Cancer Biomarkers Collaborative consensus report: advancing the use of biomarkers in cancer drug development
    Samir N Khleif
    National Cancer Institute, Raritan, New Jersey, USA
    Clin Cancer Res 16:3299-318. 2010
    ....